Cogent Biosciences Inc

NASDAQ COGT

Download Data

Cogent Biosciences Inc Operating Cash Flow to Debt Ratio 5 year CAGR for the quarter ending September 19, 2024

Cogent Biosciences Inc Operating Cash Flow to Debt Ratio 5 year CAGR is NA for the quarter ending September 19, 2024. The operating cash flow to debt ratio measures the ability of a company's operating cash flow to cover its total debt obligations. It is calculated by dividing the operating cash flow by the total debt. This ratio provides insights into the company's ability to generate cash flow from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating cash flow relative to the level of debt, suggesting potential financial strength and debt servicing capability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: COGT

Cogent Biosciences Inc

CEO Mr. Andrew R. Robbins M.B.A.
IPO Date March 29, 2018
Location United States
Headquarters 200 Cambridge Park Drive, Cambridge, MA, United States, 02140
Employees 164
Sector Healthcare
Industry Biotechnology
Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Similar companies

KURA

Kura Oncology Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

KALV

Kalvista Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email